<DOC>
	<DOCNO>NCT00236626</DOCNO>
	<brief_summary>The purpose study investigate ( 1 ) effect topiramate insulin sensitivity overweight obese patient type 2 diabetes mellitus ( 2 ) safety topiramate type 2 diabetic patient . The study also investigate effect topiramate body weight , body fat , fat distribution , metabolic control include glucose lipid level .</brief_summary>
	<brief_title>A Study Safety Effectiveness Topiramate Insulin Sensitivity Overweight Obese Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Topiramate approve treatment obesity . This double-blind , placebo control study investigates effect topiramate insulin sensitivity overweight obese patient Type 2 Diabetes . After screen phase , patient randomize receive either topiramate ( 96 milligram [ mg ] twice daily ) placebo 9 month double-blind phase . After 9 month , patient option continue open-label phase receive treatment topiramate 1 year . Patients placebo group receive topiramate dosage increase gradually 96 mg twice daily , option increase 256 mg twice daily . Patients topiramate group continue maintenance dose receive double-blind phase , option increase 256 mg twice daily . Assessments effectiveness make monthly include insulin sensitivity , body composition ( measure compute tomography [ CT ] ) , body weight Body Mass Index ( BMI ) , waist hip circumference , fast lipid profile , fast glucose hemoglobin type A1c ( HbA1c ) level , blood pressure . Safety evaluation , include incidence adverse event , clinical laboratory result , vital sign , electrocardiograms [ ECGs ] ) , perform throughout study . The study hypothesis topiramate improve insulin sensitivity type 2 diabetic patient well tolerate . Patients randomize receive 192 mg/day ( 96mg twice daily ) topiramate , placebo , per mouth 9 month , option topiramate treatment increase 256mg/day group extension period 1 year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Patients must history Type 2 diabetes 6 month , treat either diet alone sulfonylurea least 6 month Hemoglobin A1c 6.5 % 10 % BMI 27 50 Nonsmokers Female patient must postmenopausal least 1 year , surgically incapable childbearing , practice acceptable method contraception Unstable endocrine disease Significantly abnormal liver function kidney function History schizophrenia , major depressive disorder eat disorder History epilepsy , kidney stone substance ( alcohol ) abuse</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Obesity</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Body Mass Index</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Sulfonylurea</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Adult-Onset Diabetes Mellitus</keyword>
	<keyword>Metabolic Syndrome</keyword>
</DOC>